Aclarion, Inc., a Delaware-incorporated medical laboratories service provider, announced the results of its annual stockholders meeting held on December 31, 2024. The meeting saw the election of seven directors and the approval of several significant proposals, including a reverse stock split and amendments to the company's equity incentive plan.
Shareholders voted in favor of all seven director nominees, with Jeffrey Thramann receiving 1,189,506 votes for and 107,489 withheld. The other directors, Brent Ness, Stephen Deitsch, Scott Breidbart, David Neal, William Wesemann, and Amanda William, were also elected with similar vote counts and broker non-votes.
The ratification of Haynie & Company as the independent registered accounting firm passed with an overwhelming majority, gathering 3,776,879 votes for and only 250,987 against.
The approval of the issuance of shares pursuant to the company's equity line was sanctioned with 1,129,322 votes for, 164,731 against, and 2,941 abstentions. Additionally, the issuance of shares related to the company's Series B and Series C convertible preferred stock and related warrants was approved.
A significant development was the approval of a proposed reverse stock split, which received 3,006,776 votes for and 1,016,688 against, with 15,072 abstentions.
Furthermore, an amendment to Aclarion’s 2022 equity incentive plan was approved, with 1,074,285 votes for, 202,442 against, and 20,268 abstentions.
The news above is based on an SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.